Fig. 4From: HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC resultsTreatment outcome based on HER2/CEP17 ratio and HER2 IHC. A Progression-free survival according to HER2/CEP17 ratio in HER2 IHC 1+/2+ (n = 23) and B HER2 IHC 3+ (n = 55). C Overall survival according to HER2/CEP17 ratio in HER2 IHC 1+/2+ (n = 23) and D HER2 IHC 3+ (n = 55)Back to article page